CTNNB1 and hepatocellular carcinoma: In HCC, Wnt/CTNNB1 mutations characterize the immune excluded class and WNT activation leads to T-lymphocyte exclusion, making it a predictive biomarker of intrinsic innate resistance to ICI therapy in HCC (29).